Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

Comprehensive Insights into Diabetes Mellitus: Diagnosis, Management, and Emerging Trends

Afshana Qadir[1*], Mohd Altaf Dar[2], Zulfkar Qadrie[3], Humaira Ashraf[4]

[1]Nursing Tutor, Government College of Nursing Baramulla, India.*
[2]Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.
[3]Department of Pharmacology, Government Medical College, Baramulla, India.
[4]Department of Animal Nutrition, SKUAST-K, Srinagar, India.

Corresponding Email: [1]qadirafshana3@gmail.com*

Received: 04 August 2022 **Accepted:** 17 October 2022 **Published:** 23 November 2022

Abstract: ***Diabetes mellitus is a common and long-lasting metabolic condition characterised by consistently high blood sugar levels caused by problems with insulin production, insulin function, or both. This article offers a thorough examination of diabetes mellitus, including its different types, underlying physiological processes, variables that contribute to its development, symptoms experienced by patients, criteria used for diagnosis, and tactics employed for its management. The main categories of diabetes are Type 1 Diabetes Mellitus (T1DM), an autoimmune disorder that results in insufficient insulin production; Type 2 Diabetes Mellitus (T2DM), characterised by insulin resistance and inadequate insulin production; and Gestational Diabetes Mellitus (GDM), which occurs during pregnancy and presents risks to both the mother and the baby. Monogenic diabetes, although less common, also deserves attention because of its distinct care needs. The review explores the pathophysiological underpinnings of each kind, emphasising the interaction between genetic, environmental, and metabolic factors. The discussion focuses on risk factors, including genetic predisposition, obesity, and lifestyle choices, and their relationship to the development of diseases. The clinical manifestations of this condition differ depending on the kind, but typically include symptoms such as increased thirst, frequent urination, and exhaustion. In cases where the condition is poorly controlled, problems such as cardiovascular disease and neuropathy may arise.***

Keywords: Diabetes Mellitus, Hyperglycemia, Insulin Resistance, Management Strategies.

1. INTRODUCTION

Diabetes mellitus is a persistent and intricate metabolic illness that impacts a large number of individuals globally. It is characterised by high levels of glucose in the blood due to

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

deficiencies in the secretion or action of insulin, or both. Diabetes has become widespread to the point of being considered an epidemic, posing a serious worldwide public health concern. Gaining knowledge about the different types of diabetes, its underlying physiological processes, variables that increase the likelihood of developing the disease, symptoms experienced by patients, criteria used for diagnosis, and strategies for treatment is essential for effectively managing the condition and enhancing patient results [1-5]. Diabetes mellitus can be divided into three main types: Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), and Gestational Diabetes Mellitus (GDM). There is also a less frequent but important group known as monogenic diabetes. Type 1 Diabetes Mellitus is an autoimmune disorder characterised by the erroneous targeting and destruction of the insulin-producing beta cells in the pancreas by the body's immune system. This leads to a complete lack of insulin, resulting in elevated levels of glucose in the blood. Type 1 diabetes mellitus (T1DM) usually appears during childhood or adolescence and necessitates continuous insulin treatment to regulate blood sugar levels and avoid complications [5-10].
The most prevalent kind of diabetes, known as kind 2 Diabetes Mellitus, often occurs in adults but is becoming more common in younger populations due to the growing rates of obesity and sedentary lifestyles. Type 2 diabetes mellitus (T2DM) is distinguished by a condition called insulin resistance, in which the cells of the body fail to respond adequately to insulin, along with a relative insufficiency in the synthesis of insulin. This type of diabetes is frequently linked to obesity, lack of physical activity, and unhealthy eating patterns. The insidious beginning of Type 2 diabetes mellitus (T2DM) implies that it might remain undetected for an extended period, hence increasing the likelihood of enduring long-term consequences such as cardiovascular disease, neuropathy, nephropathy, and retinopathy [10-12]. Gestational Diabetes Mellitus is a condition that develops during pregnancy and is characterised by high levels of glucose in the blood that either develop or are first identified during pregnancy. Gestational diabetes mellitus (GDM) presents substantial concerns for both the mother and the baby, such as an elevated probability of developing preeclampsia, giving birth to a big baby, and experiencing neonatal hypoglycemia. Women who have previously had gestational diabetes mellitus (GDM) are more likely to develop Type 2 Diabetes in the future. Postpartum resolution of the illness is common, but, there is still an increased risk of developing diabetes in the future. This emphasises the need for ongoing monitoring and making lifestyle changes. Monogenic diabetes, although less common than type 1 diabetes (T1DM) and type 2 diabetes (T2DM), include disorders such as Neonatal Diabetes Mellitus (NDM) and Maturity-Onset Diabetes of the Young (MODY). These types of diabetes are caused by specific genetic abnormalities that impact the generation or function of insulin [12-15]. They often have distinct clinical characteristics and require specialised therapy. Gaining comprehension of these uncommon variations of diabetes is crucial for precise identification and suitable management [15].
The pathophysiology of diabetes mellitus is characterised by an intricate interaction of genetic, environmental, and metabolic variables. Type 1 Diabetes Mellitus is characterised by the interaction between genetic predisposition and environmental triggers, such as viral infections. This interaction ultimately results in an autoimmune response that specifically targets and destroys beta cells. Type 2 Diabetes Mellitus is characterised by a condition called insulin resistance, in which the body's cells become less sensitive to the effects of

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

insulin. Hyperglycemia is sometimes worsened by malfunction of the beta-cells, which occurs alongside resistance. Obesity, physical inactivity, and genetic predisposition are significant factors that contribute to the development of insulin resistance [16-18]. Gestational Diabetes Mellitus is thought to arise from the hormonal fluctuations that occur during pregnancy, which cause a reduced response to insulin. The placenta secretes hormones that counteract the effects of insulin, requiring elevated amounts of insulin to regulate blood glucose levels within the normal range. Gestational diabetes mellitus (GDM) occurs when the pancreatic beta cells are unable to fulfil the higher demand.

Various risk factors contribute to the development of diabetes mellitus, including genetic predisposition, lifestyle variables, and environmental influences. Genetic predisposition is a major factor in the development of Type 1 and Type 2 diabetes, as specific genes might make individuals more susceptible to these conditions. Obesity, lack of physical activity, and unhealthy eating habits significantly contribute to the onset of Type 2 Diabetes Mellitus. Risk factors for Gestational Diabetes Mellitus include obesity, maternal age above the average, and a familial predisposition to diabetes [18-20]. The clinical presentations of diabetes mellitus differ depending on the type, but commonly encompass symptoms such as polydipsia (excessive thirst), polyuria (frequent urination), unexplained weight loss, and exhaustion. Type 1 Diabetes Mellitus is characterised by the rapid development of symptoms, which may be accompanied by diabetic ketoacidosis (DKA), a severe complication characterised by metabolic acidosis and the generation of ketones. In patients with Type 2 Diabetes Mellitus, symptoms may manifest gradually and can be inconspicuous, commonly include hazy eyesight, delayed wound healing, and frequent infections. Poorly managed diabetes can result in severe health problems in the long run, such as cardiovascular disease, neuropathy, nephropathy, and retinopathy.

The diagnosis of diabetes mellitus relies on various factors, such as fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and HbA1c levels. Precise diagnosis is essential for efficient treatment and to halt the advancement of the illness and the emergence of complications. Strategies for managing diabetes mellitus encompass lifestyle adjustments, medicine, and consistent monitoring. Diabetes care relies on essential elements such as dietary modifications, regular physical exercise, and effective weight control. The pharmacotherapy for Type 1 Diabetes Mellitus mostly relies on insulin as a fundamental treatment, while Type 2 Diabetes Mellitus offers a broader selection of oral and injectable drugs. Gestational Diabetes Mellitus is controlled by making changes to the diet and, if needed, with insulin therapy.

Current developments in diabetes research encompass the creation of novel pharmaceuticals, progress in glucose monitoring devices, and inventive treatment methodologies. Investigations exploring potential vaccines for Type 1 Diabetes Mellitus, innovative drug categories for Type 2 Diabetes Mellitus, and progress in gene therapy and regenerative medicine provide potential for enhancing diabetes management and patient outcomes [20-22].

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

2. RELATED WORKS

The field of diabetes mellitus research is vast, covering a wide range of studies that investigate many elements of the condition, such as its underlying mechanisms, variables that increase the chance of developing it, tactics for treating it, and new medicines that are being developed. This review presents significant discoveries and progress that have enhanced our comprehension of diabetes mellitus. Studies on Type 1 Diabetes Mellitus (T1DM) have yielded valuable knowledge about its autoimmune characteristics and genetic foundations. Research has clarified the significance of genetic susceptibility in Type 1 Diabetes Mellitus (T1DM), by finding several areas of the genome that are linked to an increased risk of developing the disease [22-24]. These genetic discoveries have opened the door for focused investigation into preventative and curative approaches. Furthermore, researchers have investigated the autoimmune mechanisms that cause the loss of beta cells. They have shown that environmental triggers, including as viral infections, could potentially launch the autoimmune process in persons who are genetically predisposed. This finding has ramifications for the advancement of new vaccines and immunotherapies that target the prevention or cessation of T1DM [24-25]. Research in the field of Type 2 Diabetes Mellitus (T2DM) has enhanced our comprehension of insulin resistance and beta-cell malfunction. Research has shown that insulin resistance, which is mostly caused by factors like obesity and a sedentary lifestyle, is a crucial characteristic of type 2 diabetes mellitus (T2DM). This has led to the development of lifestyle intervention techniques that prioritise weight management and physical activity as essential elements in the prevention and management of Type 2 Diabetes Mellitus (T2DM). Moreover, investigations into genetic variables have shown many susceptibility genes that play a role in the onset of T2DM. The discoveries have resulted in progress in personalised medicine, enabling customised treatment approaches based on genetic profiles [26].

Research into medication has had a substantial impact on the management of T2DM. The efficacy of drugs like metformin in reducing blood glucose levels and enhancing insulin sensitivity has been well investigated. Recent research has shown evidence for the effectiveness of emerging categories of medications, such as SGLT2 inhibitors and GLP-1 receptor agonists, in the treatment of type 2 diabetes mellitus (T2DM). Recent clinical trials have shown that these drugs not only regulate blood glucose levels but also provide other advantages, such as promoting weight loss and offering cardiovascular protection. Research on Gestational Diabetes Mellitus (GDM) has mostly concentrated on comprehending its influence on the health of both the mother and the newborn, as well as developing effective management options. Research has demonstrated that lifestyle changes and insulin therapy can effectively decrease negative outcomes linked to gestational diabetes mellitus (GDM), such as excessive birth weight and preeclampsia. Studies have also emphasised the long-term consequences of gestational diabetes mellitus (GDM), with data indicating a heightened likelihood of having Type 2 Diabetes in the future for women who have previously had GDM. As a result, it is now recommended to screen for glucose levels after childbirth and make long-term lifestyle changes to reduce this risk [27-28].

Monogenic diabetes, despite being less prevalent, has garnered interest because of its distinct genetic and clinical characteristics. Studies on disorders such as Maturity-Onset Diabetes of

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

the Young (MODY) and Neonatal Diabetes Mellitus (NDM) have uncovered distinct genetic alterations that impact the generation and function of insulin. These investigations have enabled the advancement of focused genetic testing and customised treatment strategies for individuals with monogenic diabetes, providing fresh perspectives on personalised diabetes management.

The progress in diabetes care brought about by technological breakthroughs, especially the creation of continuous glucose monitoring (CGM) systems, has been revolutionary. These technologies have transformed diabetes management by offering immediate glucose readings and enabling improved control over blood sugar levels [28-33]. Closed-loop insulin delivery systems, also known as artificial pancreas systems, have enhanced diabetes management by automating the administration of insulin according to continuous glucose monitoring (CGM) data. These technological advancements are enhancing the standard of living for those with diabetes and are projected to further develop through continuous study. Furthermore, continuing research is being conducted to explore possible vaccines and immunotherapies for Type 1 Diabetes Mellitus. There are ongoing efforts to create vaccine candidates that can target autoimmune reactions and perhaps prevent or delay the onset of T1DM. Research on beta-cell regeneration and transplantation is advancing, focusing on the effectiveness of islet cell transplantation and the difficulties related to the long-term survival of the graft [33-35].

3. METHODOLOGY

This study utilizes an exhaustive review methodology to thoroughly assess the existing literature on diabetes mellitus, encompassing Type 1, Type 2, and Gestational Diabetes Mellitus. The comprehensive nature of this review stems from the inclusion of a wide variety of sources, such as peer-reviewed academic articles, clinical trials, meta-analyses, systematic reviews, and expert evaluations. This approach ensures that the study incorporates a broad spectrum of perspectives and findings, thereby providing a nuanced understanding of diabetes mellitus. The review's scope extends to several critical aspects of diabetes research. First, it examines the underlying biological mechanisms of the disease, exploring the complex interactions between genetics, immunology, and metabolic processes that contribute to the onset and progression of diabetes. By doing so, the review sheds light on the pathophysiology of both Type 1 and Type 2 diabetes, as well as the distinct challenges posed by Gestational Diabetes Mellitus, which requires special consideration due to its impact on both maternal and fetal health. Second, the review rigorously analyzes the various factors that contribute to the development of diabetes. These include genetic predispositions, environmental influences, lifestyle factors, and the role of obesity and metabolic syndrome in the pathogenesis of Type 2 diabetes. The interplay between these factors is explored in depth, highlighting how they contribute to the increasing global prevalence of the disease. The review addresses the diagnostic criteria for diabetes, discussing both established and emerging methods for early detection and diagnosis. This includes an evaluation of traditional blood glucose measurements, such as fasting plasma glucose and HbA1c, as well as newer diagnostic tools and biomarkers that are being researched for their potential to improve early detection and risk stratification. The review also considers the evolving

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

guidelines for diabetes diagnosis and how they are applied in clinical practice.Fourth, the study delves into therapeutic strategies, offering a detailed examination of current treatment approaches for managing diabetes. This includes a comprehensive overview of pharmacological interventions, such as insulin therapy, oral hypoglycemic agents, and the latest drug classes like GLP-1 receptor agonists and SGLT-2 inhibitors. The review also discusses non-pharmacological interventions, including lifestyle modifications like diet and exercise, as well as emerging approaches such as bariatric surgery for obesity-related diabetes. The review covers significant advancements in medical technology, including innovations in glucose monitoring, insulin delivery systems, and the development of artificial pancreas devices. These technologies are evaluated for their potential to improve glycemic control, reduce complications, and enhance the quality of life for individuals with diabetes. The review also highlights the role of telemedicine and digital health tools in the management of diabetes, especially in the context of the ongoing global health challenges posed by the COVID-19 pandemic.

4. RESULTS AND DISCUSSION

Recent research on Type 1 Diabetes Mellitus (T1DM) has further solidified our understanding of its autoimmune origin. Research has repeatedly shown that Type 1 Diabetes Mellitus (T1DM) is caused by the immune system attacking and destroying the beta cells in the pancreas that produce insulin. Through genetic study, multiple risk loci have been found that are linked to T1DM, thereby expanding our understanding of its hereditary characteristics. The genetic information has played a crucial role in identifying individuals who are more susceptible to certain risks and in devising viable preventive strategies. Environmental triggers, such as viral infections, have been highlighted as playing a significant role in initiating or speeding up the autoimmune process in those who are genetically predisposed. These findings provide further support for ongoing research on vaccines and immunotherapies that target the prevention or alteration of the autoimmune response in T1DM [35-37].

Regarding management, insulin therapy continues to be the fundamental approach for treating T1DM. Recent research emphasises the efficacy of continuous glucose monitoring (CGM) systems in enhancing glycemic control. Continuous Glucose Monitoring (CGM) offers immediate glucose information, allowing for more accurate insulin administration and decreasing the chances of experiencing low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia). Closed-loop insulin administration systems, also known as artificial pancreas systems, are a major breakthrough in the management of Type 1 Diabetes Mellitus (T1DM). These systems automate the delivery of insulin by using Continuous Glucose Monitoring (CGM) data, resulting in enhanced control of blood sugar levels. These advancements are anticipated to improve the quality of life for people with T1DM by lessening the weight of daily diabetes control. Research on Type 2 Diabetes Mellitus (T2DM) has primarily concentrated on comprehending the processes behind insulin resistance and beta-cell malfunction. Research has validated that insulin resistance, mostly caused by obesity and lack of physical activity, is a key characteristic of type 2 diabetes mellitus (T2DM). The discovery of genes that make individuals more susceptible to developing type 2

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

diabetes mellitus (T2DM) has helped us understand how genetics and lifestyle factors interact to contribute to the development of this disease [37-40]. This comprehension has influenced lifestyle intervention approaches, highlighting the significance of weight control, physical exercise, and dietary adjustments in the prevention and treatment of T2DM. The treatment of type 2 diabetes mellitus (T2DM) has made notable progress in pharmacotherapy. The efficacy of metformin in reducing blood glucose levels and enhancing insulin sensitivity has been well proven, leading to its widespread adoption. Recent research has increased the range of drugs that are available, including additional categories like as SGLT2 inhibitors and GLP-1 receptor agonists. SGLT2 inhibitors function by diminishing the reabsorption of glucose in the kidneys, resulting in decreased blood glucose levels and subsequent weight loss. GLP-1 receptor agonists improve the production of insulin, reduce hunger, and provide advantages for cardiovascular health. These drugs have been proven in clinical trials to not only enhance glycemic control but also decrease the likelihood of cardiovascular events, making them essential supplements to the treatment plan for type 2 diabetes mellitus (T2DM) [40-43]. Research on Gestational Diabetes Mellitus (GDM) has emphasised its effects on the health of both the mother and the newborn. Research has indicated that gestational diabetes mellitus (GDM) heightens the likelihood of experiencing issues such as excessive foetal growth (macrosomia), high blood pressure during pregnancy (preeclampsia), and giving birth prematurely. Efficient control options encompass dietary adjustments, physical exercise, and, if necessary, insulin medication. Studies have demonstrated that lifestyle modifications can effectively decrease negative consequences related to GDM, such as excessive birth weight and preeclampsia. Furthermore, studies have highlighted the significance of conducting postpartum glucose screening for women who have already experienced gestational diabetes mellitus (GDM), as they have a higher likelihood of acquiring Type 2 Diabetes in the future. As a result, it is advised to implement long-term monitoring and make lifestyle changes in order to reduce this risk. Monogenic diabetes, although less prevalent, has garnered attention in scientific investigations due to its distinctive genetic characteristics. Research on Maturity-Onset Diabetes of the Young (MODY) and Neonatal Diabetes Mellitus (NDM) has discovered precise genetic abnormalities that impact the synthesis and function of insulin [43-44]. This research has enabled the advancement of focused genetic testing, enabling precise diagnosis and customised treatment strategies. For individuals diagnosed with monogenic diabetes, it is essential to identify the precise genetic mutation in order to determine the most optimal approach to managing the condition. This may involve prescribing specific drugs or making targeted lifestyle modifications that are customised to their unique genetic makeup. The progress in technology has had a profound impact on improving diabetes care. CGM systems have proven essential in managing diabetes by offering real-time glucose readings and enhancing glycemic control. Closed-loop insulin delivery systems have improved diabetes management by automating insulin administration using CGM data, hence decreasing the likelihood of hypoglycemia and hyperglycemia. These technological advancements signify a notable transition towards diabetes management that is tailored to individual needs and more efficient in its outcomes.

Ongoing research on possible vaccines and immunotherapies for Type 1 Diabetes Mellitus shows promise for future prevention and treatment possibilities. Current endeavours are in progress to create vaccinations that specifically target autoimmune reactions in order to

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

prevent or postpone the occurrence of T1DM. Ongoing research is being conducted on the regeneration and transplantation of beta cells. These studies are investigating the effectiveness of islet cell transplantation and addressing the difficulties associated with the long-term survival of transplanted grafts. These breakthroughs have the potential to enhance the management and treatment of diabetes mellitus [44].

5. CONCLUSION

Affecting millions of people with its several forms—Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), and Gestational Diabetes Mellitus (GDM)—diabetes mellitus remains a major worldwide health concern. Our knowledge of the pathophysiology, risk factors, and treatment approaches of the disease has been much increased by recent study. More successful therapy techniques have been guided by insights into the autoimmune destruction of beta cells in T1DM, the mechanisms of insulin resistance in T2DM, and the effects of GDM on mother and newborn health. Technology has advanced diabetes therapy by means of closed-loop insulin delivery systems and continuous glucose monitoring, therefore providing better glycemic control and higher patient quality of life. Future prevention and therapy also benefit from new studies on vaccines, fresh drugs, and creative therapies. Notwithstanding these developments, continuous study is absolutely vital to close present gaps and improve present approaches. A thorough knowledge of diabetes and its care will always change and emphasises the need of ongoing study and invention to better control the condition and raise patient outcomes. Reducing the worldwide load of this chronic illness and improving treatment depend on addressing diabetes mellitus using a multifarious strategy.

6. REFERENCES

1. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine. 2017 Jul 11;53(2):151-6.
2. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2021 Jul 22;34(2):1-9.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. International Journal of Adolescent Medicine and Health. 2021 Jun 18;33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24.
5. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):367-73.
6. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. Asian Journal of Pharmaceutical Research and Development. 2019 Feb 15;7(1):66-9.

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

7. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021 Apr 21;33(6):333-7.
8. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):641-4.
9. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery. 2021 Dec 1;72:103077.
10. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-7.
11. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022 May 2;3(1):60-5.
12. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health. 2021 Jul 22;34(2):11-7.
13. Maqbool M, Rasool S, Dar MA, Bashir R, Khan M. Hepatotoxicity and Hepatoprotective agents: A Mini review. PharmaTutor. 2019 Sep 1;7(9):34-40.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of Nigella sativa L., a wonder herb. Journal of Applied Pharmaceutical Sciences and Research. 2020;3(4):04-13.
15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Sep 1;5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED. 2021;11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 May 18;1(3):95-101.
18. Maqbool M, Fekadu G, Dugassa D, Bekele F, Turi E, Simegnew D. The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital, Jammu and Kashmir, India. Archives of Neuroscience. 2020 Oct 31;7(4).
19. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:8-18.
20. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. Journal of Pharmaceutical Research International. 2021 Jun 10;33(31A):135-40.
21. Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool M. Drug use evaluation of beta-blockers in medical wards of Nedjo general hospital, Western Ethiopia. Cardiovascular Therapeutics. 2020 Jun 1;2020.

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

22. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):983-7.
23. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. Open Health. 2022 Jan 1;3(1):114-9.
24. Maqbool M, Dugassa D, Fekadu G. Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. Archives of Neuroscience. 2021 Apr 30;8(2).
25. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. CELLMED. 2021;11(1):6-1.
26. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):15-9.
27. Dar MA, Maqbool M, Rasool S. Pharmaceutical wastes and their disposal practice in routine. Int J InfComput Sci. 2019 Apr;6:76-92.
28. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127.
29. Maqbool M, Dar MA, Rasool S, Gani I, Khan M. Substance use disorder and availability of treatment options: an overview. Journal of research in health science. 2019;1:4-10.
30. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.
31. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.
32. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.
33. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8060-5.
34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.
35. Maqbool M, Zehravi M, Maqbool R, Ara I. An overview about treatment of gestational diabetes mellitus: A short communication. CELLMED. 2021;11(3):12-.
36. Fekadu G, Gamachu B, Mengie T, Maqbool M. Knowledge, attitude of health care professional's towards clinical pharmacy services in Nedjo General Hospital, Western Ethiopia. International Journal. 2019 Jul;5(7):172.
37. Maqbool M. Evaluation of drug utilization pattern in the pediatric department of a Tertiary Care Hospital in Srinagar, Jammu & Kashmir, India. Journal of Applied Pharmaceutical Sciences and Research. 2019:6-9.

Journal of Prevention, Diagnosis and Management of Human Diseases
ISSN: 2799-1202
Vol: 02, No. 06, Oct-Nov 2022
http://journal.hmjournals.com/index.php/JPDMHD
DOI: https://doi.org/10.55529/jpdmhd.26.15.25

38. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. Journal of Pharmacy Practice and Community Medicine. 2018;4(4).
39. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:19-31.
40. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation. 2021 Dec 31;1(1).
41. Maqbool M, Arshad B, Liaquat S. Psychotropic drug utilisation pattern can be useful in monitoring treatment regimens for mental disorders in psychiatric settings. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Aug 1;5(8):7717-21.
42. Zehravi M, Maqbool M, Ara I. Unfolding the mystery of premenstrual syndrome (PMS): an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):9-13.
43. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics. 2021 Jul:408-18.
44. Ara I, Kalam MA, Maqbool M, Zehravi M. Phytochemical Standardization and Anti-Anxiety (Izterab-e-Nafsani) study of Aftimoon Hindi (CuscutareflexaRoxb.) on An Animal Model. CELLMED. 2021;11(3):14-.